Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.
about
Interaction of tumor cells with the microenvironmentTargeting the Notch signaling pathway in cancer therapeuticsToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesSingle amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasionSelecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane ProteinsNeutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzymeElongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasionPertussis Toxin Is a Robust and Selective Inhibitor of High Grade Glioma Cell Migration and Invasion.A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR)u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progressionRole of urokinase receptor in tumor progression and development.The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single targetMultifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cellsAntibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.Clinical opportunities and challenges in targeting tumour dormancy.Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.Brief overview of selected approaches in targeting pancreatic adenocarcinoma.Mechanisms regulating glioma invasion.Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell lineInhibition of uPAR-TGFβ crosstalk blocks MSC-dependent EMT in melanoma cells.Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.Snail mediates invasion through uPA/uPAR and the MAPK signaling pathway in prostate cancer cellsThe receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis.Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray study.Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.
P2860
Q21245506-4F732584-4388-43F1-9037-C7F068ADC272Q26863580-98883C5E-AED1-491B-BE27-FBE4E818FD88Q26995399-EE0B641B-9301-452D-A0B3-6C5D0B23520DQ27319474-3B37625C-8746-4F0A-9D80-FAA7786B0958Q28077999-8D70C382-D014-4833-BAE1-D503C5CC164FQ30361219-8729CC3E-733C-4A49-8865-A7D59083879AQ33977030-8E2B3146-AE67-4A9C-8899-A94A3F1DC61BQ34473662-9CFD2F72-7FC3-4365-B082-2DFF1812D3C8Q36225233-CEC0BF44-D5B6-492F-A236-343D41864A0DQ36298409-AEED4CD5-CE5F-4BDF-B68F-7A4A5FCCD8E2Q36322476-3625E84C-3B5E-47DF-BB55-EE8CC9BA0D60Q36997616-6B395365-0968-4A9F-91B9-9204F519617EQ36997621-2FC915B0-F27A-44E8-83CA-F1384A29915DQ37131462-3BF9DC25-3AE8-4423-B72B-941743449358Q37451733-712698D1-8040-4925-BAB0-919445DA9E0FQ37548974-E3E90C54-3C53-4D7F-B262-33FC785EF18EQ37687496-38652561-54D0-4196-851D-CB8DED123905Q38062792-8B0A1158-634F-431A-93DE-1D3E712316C8Q38120755-98FCE699-4337-4D98-A807-41FBBFA89EB9Q38199723-CC383EAE-185B-49F4-811D-6ECABB6A0633Q38386429-6072C5C4-799D-4343-AE08-A9F99B05AE96Q38666705-628CA933-E3CF-4858-A960-C172ACCA2D1EQ38817198-3C8C4A80-AF0D-441F-9EF6-E55B938D34ECQ38908272-B7DBD315-2B85-40F8-A894-04316AFF743DQ38963363-8E7FD17E-67D8-4B37-B87E-93F2E0D4B9C4Q39988571-084A21C7-1230-445C-8519-196F418DC133Q40087550-AF603078-30A9-4302-A7C0-37F22D8D1A46Q41093581-72A4869D-B634-4EB5-9A50-999F60C08BD1Q45835023-3C7830EC-53B4-49F1-97A6-4A3D4EB2D563Q47126059-AB477B8B-FADA-42DD-8DA2-8340EFB6870DQ51335207-8AF25C25-3143-4F5E-BFE3-B18B4B15D6A3Q54960825-4057FA75-EB5D-4F2A-8028-556D347F46EAQ55378421-9DEC5154-B9C2-4F27-B44C-28BD2D448B9C
P2860
Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of novel therapeut ...... translation toward the clinic.
@en
Development of novel therapeutics targeting the urokinase plasminogen activator receptor
@nl
type
label
Development of novel therapeut ...... translation toward the clinic.
@en
Development of novel therapeutics targeting the urokinase plasminogen activator receptor
@nl
prefLabel
Development of novel therapeut ...... translation toward the clinic.
@en
Development of novel therapeutics targeting the urokinase plasminogen activator receptor
@nl
P2093
P2860
P1476
Development of novel therapeut ...... translation toward the clinic.
@en
P2093
Andrew P Mazar
Richard W Ahn
Thomas V O'Halloran
P2860
P304
P356
10.2174/138161211796718152
P577
2011-01-01T00:00:00Z